#1 Clinical Trials Search in Europe

Betamethasone Sodium Phosphate Ph. Eur

This article explores the use of Betamethasone Sodium Phosphate Ph. Eur. in several clinical trials focused on treating different types of cancer. The drug is being studied as part of combination therapies for conditions including multiple myeloma, non-small cell lung cancer, ovarian cancer, and various rare B-cell malignancies. These trials aim to evaluate the safety and efficacy of novel treatment approaches for patients with advanced or relapsed/refractory cancers.

Table of Contents

What is Betamethasone Sodium Phosphate?

Betamethasone sodium phosphate is a synthetic corticosteroid medication. It’s a potent anti-inflammatory and immunosuppressive drug used to treat various medical conditions. Betamethasone sodium phosphate is also known by its synonym, dexamethasone sodium phosphate.[1]

Medical Uses

Betamethasone sodium phosphate is used in the treatment of several conditions, including:

  • Multiple myeloma[1]
  • Non-small cell lung cancer[5]
  • Ovarian cancer[6]
  • Inflammatory conditions
  • Autoimmune disorders
  • Allergic reactions

It’s often used in combination with other medications as part of cancer treatment regimens or to manage side effects of cancer therapies.[2][3][4]

How It Works

Betamethasone sodium phosphate works by mimicking the effects of natural hormones produced in your adrenal glands. It reduces inflammation and suppresses the immune system, which can be beneficial in treating various conditions. In cancer treatment, it can help manage symptoms and side effects of other therapies.[1]

Administration

Betamethasone sodium phosphate can be administered in several ways:

  • Orally (by mouth)[5]
  • Intravenously (IV, directly into a vein)[1][2][3][4]

The method of administration depends on the specific condition being treated and the treatment protocol prescribed by your doctor.

Dosage

The dosage of betamethasone sodium phosphate varies widely depending on the condition being treated, the patient’s age and overall health, and other factors. In clinical trials, dosages have ranged from:

Always follow your doctor’s instructions regarding dosage. Never adjust your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, betamethasone sodium phosphate can cause side effects. Common side effects may include:

  • Increased appetite
  • Weight gain
  • Mood changes
  • Insomnia
  • Increased blood sugar levels
  • Fluid retention

More serious side effects can occur, especially with long-term use or high doses. These may include:

  • Increased risk of infections
  • Osteoporosis (bone thinning)
  • Adrenal suppression
  • High blood pressure
  • Cataracts or glaucoma

Always report any unusual symptoms or side effects to your healthcare provider.

Precautions and Contraindications

Betamethasone sodium phosphate may not be suitable for everyone. It should be used with caution in patients with:

  • Active infections
  • Diabetes
  • Osteoporosis
  • High blood pressure
  • Glaucoma
  • History of stomach ulcers

Inform your doctor about all your medical conditions and any medications you’re taking before starting treatment with betamethasone sodium phosphate.

Current Clinical Trials

Betamethasone sodium phosphate is currently being studied in several clinical trials for various conditions:

  • Multiple myeloma: In combination with other drugs for newly diagnosed low-risk multiple myeloma[1]
  • Waldenstrom macroglobulinemia: As part of a treatment regimen for relapsed/refractory disease[2]
  • Richter transformation: In a study for relapsed/refractory cases[3]
  • Burkitt lymphoma: For relapsed/refractory disease[4]
  • Non-small cell lung cancer: In combination with other therapies for advanced disease[5]
  • Ovarian cancer: As part of a treatment regimen for high-grade serous ovarian cancer[6]

These trials aim to explore new ways to use betamethasone sodium phosphate in combination with other treatments to improve outcomes for patients with various types of cancer.

Trial Number Cancer Type Primary Objective Betamethasone Sodium Phosphate Ph. Eur. Use
2022-500453-16-00 Multiple Myeloma Determine non-inferiority of experimental arm vs standard of care Supportive care in combination therapy
2022-501259-10-00 Waldenstrom Macroglobulinemia Evaluate efficacy of brexucabtagene autoleucel Corticosteroid for managing side effects
2022-501260-18-00 Richter Transformation Evaluate efficacy of brexucabtagene autoleucel Corticosteroid in combination therapy
2022-501261-46-00 Burkitt Lymphoma Evaluate efficacy of brexucabtagene autoleucel Corticosteroid for systemic use
2022-501262-21-00 Hairy Cell Leukemia Evaluate efficacy of brexucabtagene autoleucel Corticosteroid in combination therapy
2022-501863-41-00 Non-Small Cell Lung Cancer Compare PFS of sotorasib vs pembrolizumab with chemotherapy Corticosteroid for systemic use
2022-502983-19-00 Ovarian, Fallopian Tube, or Peritoneal Cancer Investigate antitumor activity of ZN-c3 Supportive care in combination therapy

FAQ

  • What is Betamethasone Sodium Phosphate Ph. Eur. used for in these clinical trials? Betamethasone Sodium Phosphate Ph. Eur. is used as a supportive medication in combination with other cancer treatments. It helps manage side effects and improve the overall effectiveness of the primary cancer therapies being studied.
  • What types of cancers are being studied in these trials? The trials are investigating treatments for multiple myeloma, non-small cell lung cancer, ovarian cancer, Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia.
  • How is Betamethasone Sodium Phosphate Ph. Eur. administered in these trials? The drug is administered either orally or intravenously, depending on the specific trial protocol and the patient's condition.
  • What are the main objectives of these clinical trials? The main objectives include evaluating the safety and efficacy of new combination therapies, determining response rates, assessing progression-free survival, and comparing new treatments to existing standards of care.
  • Are these trials open to all cancer patients? No, each trial has specific eligibility criteria. Patients must meet certain requirements related to their cancer type, stage, previous treatments, and overall health status to participate in these studies.

Ongoing Clinical Trials on Betamethasone Sodium Phosphate Ph. Eur

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Italy Poland Spain

  • Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy The Netherlands +3

  • Study on Ruxolitinib and Drug Combination for Critically Ill Adults with Acquired Hemophagocytic Syndrome

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on Dexamethasone for Patients with Moderate to Severe Depression: Evaluating Its Effectiveness with Mirtazapine, Citalopram, and Nortriptyline

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Italy Poland +1

  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia France Germany The Netherlands Poland Spain

  • Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Denmark France Germany Greece Italy +1

  • Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Betamethasone Sodium Phosphate Ph. Eur.: A corticosteroid medication used in cancer treatments to help manage side effects and enhance the effectiveness of other therapies.
  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell in the bone marrow.
  • Non-Small Cell Lung Cancer (NSCLC): A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope.
  • Waldenstrom Macroglobulinemia: A rare type of blood cancer that begins in the white blood cells called B lymphocytes.
  • Richter Transformation: A rare condition where chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) transforms into an aggressive form of lymphoma.
  • Burkitt Lymphoma: A rare but aggressive B-cell non-Hodgkin lymphoma that can affect multiple organs.
  • Hairy Cell Leukemia: A rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes).
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-isatuximab-lenalidomide-bortezomib-and-dexamethasone-for-patients-with-newly-diagnosed-low-risk-multiple-myeloma/
  2. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-waldenstrom-macroglobulinemia-using-a-drug-combination/
  3. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-richter-transformation-rt/
  4. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-or-refractory-burkitt-lymphoma/
  5. http://clinicaltrials.eu/trial/study-comparing-sotorasib-and-pembrolizumab-with-chemotherapy-for-advanced-non-small-cell-lung-cancer-in-patients-with-kras-p-g12c-mutation-and-no-pd-l1/
  6. http://clinicaltrials.eu/trial/study-on-the-effects-of-zn-c3-for-patients-with-high-grade-serous-ovarian-fallopian-tube-or-primary-peritoneal-cancer/